Greg West | CEO |
David Suhy | Chief Scientific Officer |
Georgina Kilfoil | Chief Development Officer |
Thank you for standing by and welcome to the Benitec Biopharma Quarterly Corporate Update Conference Call. If we make any forward-looking statements we know as that such statements involve risk and uncertainties relating to the difficulties in our plans to develop and commercialize our product candidates, the timing of the initiation and completion of preclinical and clinical trials, the timing of patient enrollment and dosing in clinical trials, the timing of expected regulatory filings, the clinical utility and potential attributes and benefits of ddRNAi and our products to candidates potential future out licenses and collaborations, our intellectual property position and the ability to procure it additional process of financing. All participants are in a listen-only mode. There will be a presentation followed by a question-and-answer session. [Operator Instructions] I would now like to turn the floor over to your first speaker today Mr.